FILGRASTIM
BRCA2 Mutation
General Oncology, Inc.protein_peptidePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
15 Active assets in the BRCA2 Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Olaparib GBG Forschungs GmbH | Phase 3 | BB |
Ovitrelle University Hospital, Ghent | Phase 4 | BB |
Carboplatin Okayama University | Phase 2 | B |
Xeomin® Mayo Clinic | Phase 3 | B |
Irinotecan University of California, San Francisco | Phase 2 | B |
View all 24 →
Same molecule, other indications
FILGRASTIM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →